Clinical Trial

Study of LW231 in Participants With Chronic Hepatitis B

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2025-09-28
Trial Details
NCT Number NCT07179575
Lead Sponsor Shanghai Longwood Biopharmaceuticals Co., Ltd.
Conditions Chronic HBV Infection
Enrollment 270 participants
Start Date 2025-10
Primary Completion 2027-03 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-10-02